ADVERTISEMENT

Stay up to date every week with the european biotechnology newsletter.

✕
This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent

Stay up to date every week with the european biotechnology newsletter.

Log in here to read the desired article.

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent
go to the article

go back to the homepage

  • Subscription
  • Newsletter
  • Advertise
European Biotechnology Magazine
biocom_logo
  • Latest news
  • Background
  • Opinion
  • The Mag
    • Issues
    • Special
    • Corporate publications
    • Subscribe
  • Euro Biotech Guide
  • Market Place
    • Products
    • Sponsored Publications
    • Advertise
  • Associations
  • Service
    • Newsletter
    • Contact Us
    • Editorial Team
  • Events
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

ADVERTISEMENT

Fresenius flag
biosimilar

Fresenius turns to WuXi to add up to 37 biosimilars to its pipeline

Fresenius has secured options on 37 biosimilars from WuXi Biologics, significantly expanding its biopharma ambitions through a development agreement. The deal comes as numerous high-selling biologics … more ➔

large reptile on the road
pancreatic cancer

Alligator sells cancer antibody for $750,000 upfront after abandoning development

Swedish biotech Alligator Bioscience has agreed to sell its CD40-targeting cancer immunotherapy mitazalimab to Canadian drug developer Biossil for $750,000 (€670,000) upfront, with up to $108 million … more ➔

ADVERTISEMENT

A brainstorming session in a modern, open-plan office, with sticky notes forming the shape of a lightbulb on the wall, each note a contribution to the burgeoning company's startup vision.
Outsourcing

Europe ­rethinks the CRO-CDMO model

Should a biotech hand its molecule to a single integrated partner, or build a network of specialists around it? Manufacturers and clinical providers are answering in both directions at once: some are … more ➔

Credit: Joost Melis via Genmab
cancer immunotherapy

Genmab’s $8B Merus bet passes Phase 3 test in head and neck cancer

Denmark’s Genmab said adding its bispecific antibody petosemtamab to MSD’s Keytruda (pembrolizumab) cut the risk of death by 50% versus Keytruda alone in a Phase 3 trial in first-line, PD-L1-positive … more ➔

lifebuoy
oncology

TME Pharma returns to its roots, looks to Japan to rescue NOX-A12

From Berlin biotech NOXXON through a strategic realignment and considerations of cryptocurrency investments, and now back to drug development: TME Pharma has found a potential partner for its lead drug … more ➔

European Biotechnology

1 / 4
EBM 3.2026 Autumn_cover

The autumn issue of European Biotechnology magazine asks what happens when biotech leaves Earth. Our cover story explores how microgravity could help researchers study disease, improve drug formulations … more ➔

Get a free sample copy | Abo
2 / 4

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

Get a free sample copy | Abo
3 / 4

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo
4 / 4
EB425_Cover

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo

ADVERTISEMENT

© AI
european-biotechnology-logo

NEWSLETTER


Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.


Subscribe to our free newsletter!Subscribe here

piggy bank accounting
commercial strategy

Molecular Partners halves its workforce — is money running short?

Swiss DARPin specialist Molecular Partners is shifting its entire focus to radiopharmaceuticals and plans to cut up to 55 jobs. According to the company, its cash reserves will last until the end of … more ➔

The Leadership Edit Thumbnail European Biotechnology
Appointments

Orbis and AlzeCure change CEOs; Simris hires another Heidelberg Pharma veteran

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: two CEO transitions, three medical … more ➔

ADVERTISEMENT

Sponsored Publications

1 / 2
Picture credit: Sonuvo
real estate

Where Life Science Scales in Basel

The Basel region is one of the world’s leading life-science clusters. ­Pharmaceutical companies, biotech firms and research institutions benefit from a unique combination of talent, infrastructure … more ➔

2 / 2
YUMAB multispecific antibodies
CRO & CDMO

Beyond monoclonals: Multispecific antibodies

New biologic logic – Multispecific antibodies extend targeted therapy beyond one antigen or pathway. By combining binding sites, cell recruitment and defined valencies within one molecule, they … more ➔

APPOINTMENTS

all appointments

eb.com_Jeff_Abbey_Spica_Therapeutics_CEOSpica Therapeutics
Spica Therapeutics

New CEO for the next level

The Belgian biotech company Spica Therapeutics, specialist for Macrophages biology, appointed Jeff Abbey as new Chief Executive Officer …
more ➔

EB.com_Qiagen_CEO_Jonathan_PrattQiagen
Qiagen

New CEO took over the reins

At the beginning of September, Jonathan M. Pratt succeeded Thierry Bernard as CEO of Qiagen N.V. Bernard had led the biotech pioneer …
more ➔

Samanta CimitanLonza Group
CDMO

Samanta Cimitan to (re)join Lonza from Celonic

Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and a member of the Extended Executive Committee …
more ➔

eb.com_Teresa Nunes CMO_EpilepsyGTXEpilepsyGTX
EpilepsyGTX

Clinical Development Expert has started

London-based EpilepsyGTx has appointed Dr Teresa Nunes as Chief Medical Officer (CMO) to support the continued development of the company’s …
more ➔

Photo by National Cancer Institute via Unsplash+
small molecules

Barcelona’s ALLOX raises €9.4M to turn protein maps into drug candidates

Spanish biotech ALLOX has closed a €9.4 million ($10.5 million) seed round, led by Asabys with participation from Spanish and Catalan public investors, to expand its experimental biology and AI platform … more ➔

ADVERTISEMENT

Photo by CHUTTERSNAP on Unsplash
fundraising

Exogenus secures €13M EU consortium backing for secretome therapy in osteoarthritis

Portugal-based Exogenus Therapeutics will lead a five-year, €13 million Horizon Europe project to advance its osteoarthritis candidate EXO-101 into clinical testing. more ➔

design session brainstorming
rare diseases

Idorsia launches redesigned Fabry disease trial with Nxera backing

Switzerland-based Idorsia has launched a new pivotal Phase 3 trial of lucerastat in Fabry disease, targeting kidney deposits after its first late-stage study failed to reduce nerve pain. The company … more ➔

All news
newsletter_link

EVENT


Eventbild-heidelberg-2026-boehmert[21]
November 3 @ 09:00 - 13:00in Heidelberg, Germany

IP Seminar for Life Sciences & Chemistry

How can pharmaceutical, biotech and chemical companies effectively protect innovation in a rapidly evolving European patent landscape? BOEHMERT & BOEHMERT's complimentary IP Seminar in Heidelberg explores recent developments at the Unified Patent Court (UPC), the Unitary Patent system and the European Patent Office, highlighting practical strategie ... ➔

Knowbio GmbH
  • Link to LinkedIn
  • Link to Instagram
  • Contact
  • Imprint
  • Privacy policy
Scroll to top Scroll to top Scroll to top